Showing results (361-370 of 385) with videos related to
Sort By:
Pageof 39
Vaccine|May 15, 2007
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccineSven-Eric Olsson, Luisa L Villa, Ronaldo L R Costa, et al.Lancet (London, England)|May 22, 2007
Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trialsElmar A Joura, Sepp Leodolter, Mauricio Hernandez-Avila, et al.Journal of the American Chemical Society|October 26, 2018
First Ionization Potentials of Fm, Md, No, and Lr: Verification of Filling-Up of 5f Electrons and Confirmation of the Actinide SeriesTetsuya K Sato, Masato Asai, Anastasia Borschevsky, et al.Physical Review Letters|August 19, 2024
Erratum: Nuclear Charge Radii of Silicon Isotopes [Phys. Rev. Lett. 132, 162502 (2024)]Kristian König, Julian C Berengut, Anastasia Borschevsky, et al.Physical Review Letters|May 3, 2024
Nuclear Charge Radii of Silicon IsotopesKristian König, Julian C Berengut, Anastasia Borschevsky, et al.Annals of Internal Medicine|August 19, 2016
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized TrialGregory J Dore, Frederick Altice, Alain H Litwin, et al.Nature Neuroscience|March 9, 2022
Shared computational principles for language processing in humans and deep language modelsAriel Goldstein, Zaid Zada, Eliav Buchnik, et al.The Journal of Chemical Physics|June 4, 2020
The DIRAC code for relativistic molecular calculationsTrond Saue, Radovan Bast, André Severo Pereira Gomes, et al.The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trialsEric Lawitz, Maria Buti, John M Vierling, et al.The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trialsEdward J Gane, Stephen Pianko, Stuart K Roberts, et al.Pageof 39